A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers (DFU)

Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.

Status and phase: Enrolling; Phase 2

Conditions: Diabetic Foot Ulcer

Treatments: Drug: 0.75% MDI-1228_mesylate gel plus Standard of Care; Other: Standard of Care Alone

Study type: Interventional

Funder types: Industry

Identifiers

NCT06852976

RPT-1228-101

Details and patient eligibility

About

The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.

Full description

The study is targeted to enroll approximately sixty subjects with diabetic foot ulcers. All subjects will be randomized at baseline visits at a 2:1 ratio to either receive the study treatment plus standard of care or standard of care alone.

All subjects who meet inclusion/exclusion criteria will have all ulcers treated; however, only one ulcer, the largest, will be selected as the target ulcer.

Before performing any study procedures, all potential subjects will sign an informed consent form (ICF).

The total study duration is anticipated to be up to 18 weeks, including:

• Up to a 14-day screening period
• Up to 12 weeks study treatment
• Up to 4 weeks of follow-up
• End-of-treatment visit will be performed on the last day of treatment (D84)
• End-of-Study visit will be performed at the follow-up visit (D112)

Wound photography should be dedicated to one study site personnel to control variance.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Willing and able to participate and comply with all trial requirements and able to provide signed and dated informed consent prior to initiation of any trial procedures;

2. Male or female 18-75 years;

3. Meet diagnostic criteria for a diabetic ulcer with the presence of at least one target ulcer that meets the characteristics:

   • Located on dorsal or plantar surface of foot or below the knee.
   • Wagner grade 2, ulcerated lesion at or below the knee, without systemic infection.
   • The target ulcer should be the largest, and all each individual ulcers size should be less than 25cm2. All ulcers will be treated the same as the target ulcer.
   • Target ulcers persisted for at least 12 weeks prior to enrollment and have been on standard of care for at least 4 weeks prior to enrollment.
   • There is a minimum 3cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot (post-debridement).

Exclusion criteria

1. Allergy to the main components or excipients of MDI-1228_mesylate gel, allergy to JAK inhibitors (tofacitib, baricitinib, ruxolitinib), or individuals with allergic constitution.
2. Skin ulcers or chronic wounds caused by electroshock, chemicals, radioactive material etc.
3. The target ulcer has reduced in size by ≥30% in the last 4 weeks under standard treatment.
4. Those with cancerous ulcers or connective tissue diseases including lupus erythematosus, rheumatoid arthritis, scleroderma, etc.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Control Arm

Active Comparator group

Description:

Standard of Care for Diabetic Foot Ulcer

Treatment:

Other: Standard of Care Alone

Treatment Arm

Experimental group

Description:

MDI-1228-mesylate Gel plus Standard of Care

Treatment:

Drug: 0.75% MDI-1228_mesylate gel plus Standard of Care